Get the Weekly Intelligence Brief — top committee picks every Sunday.
CHE · NYSE · STOCK

Chemed (CHE) Stock Analysis

Healthcare Updated September 06, 2026
$520.03
52W $365.21 – $557.00
66/100
$6.79B
26.1
0.51
AI Committee Verdict
Buy
66/100
Conviction: Moderate · 67% agreement · 6 analysts
+0.8%
-0.7%
1.25:1
Moderate

Is CHE Bullish or Bearish?

Bullish. Innellis AI committee rates Chemed Corp. (CHE) Buy with a composite score of 66/100 , based on 6 analysts with 67% agreement. Last updated September 06, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +8.50 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -11.50 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 6.2x prices in significant intangible value. The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • ROE of 29.4% shows genuine earnings power backing the valuation — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
  • Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock — Risk
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • News sentiment is positive (+0.20 across 5 articles, 14d) — News
Bear Case
  • Price-to-book of 6.2x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of September 06, 2026
Overall Committee Score
66/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 16%
of 192 Healthcare peers
Value Analyst neutral
59 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 29.4% shows genuine earnings power backing the valuation
− Price-to-book of 6.2x prices in significant intangible value
Growth Analyst bullish
62 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst neutral
54 / 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− MACD histogram negative -- bearish momentum
Risk Analyst bullish
80 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock
Macro Analyst bullish
80 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst bullish
64 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 5 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 66.5 to 66.5.

Comparing 2026-09-05 to 2026-09-06 (1 day apart).

Technical Analysis

RSI (14)
40.2
Neutral
MACD Histogram
-3.608
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Hh Hl
Support
$516.50
Resistance
$524.43
Bollinger %B
0.20
Inside Bands
Price vs Moving Averages
EMA 9
$525.51 Below
EMA 21
$527.51 Below
EMA 50
$511.63 Above
EMA 200
$470.23 Above

Fundamental Analysis

Valuation
19
Growth
68
Profitability
70
Financial Health
55
Cash Flow
70
Valuation
P/E Ratio 26.1×
P/B Ratio 8.40×
PEG Ratio 17.66
Dividend Yield 0.48%
52W High $557.00
52W Low $365.21
Quality & Growth
ROE 2708.1%
ROA 1617.3%
Gross Margin 3044.2%
Operating Margin 1345.6%
Revenue Growth YoY
Debt / Equity 0.40
AI Fundamental Assessment
P/E ratio of 26.1 (moderate relative to a 15-40x range); Price-to-book of 8.4x; PEG ratio of 17.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 27.1%; Return on assets of 16.2%; Net margin of 10.6%; Gross margin of 30.4%; Current ratio of 0.91 (tight short-term liquidity); Debt-to-equity of 0.40; Free cash flow per share is positive (24.11); Most recent quarter beat estimates by 7.1%; 2 consecutive earnings beats; EPS growth accelerating (-12.0% -> +7.3% QoQ); Average YoY EPS growth of 41.9%; Analyst estimates falling over recent quarters
Get the Full CHE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime